Text Size
Trial record 17 of 194 for:    Open Studies | "Cystic Fibrosis"
Previous Study | Return to List | Next Study

Effect of Glycine in Cystic Fibrosis

This study is currently recruiting participants.
Verified March 2012 by Instituto Nacional de Enfermedades Respiratorias
Sponsor:
Collaborators:
Hospital Infantil de Mexico Federico Gomez
Instituto Mexicano del Seguro Social
Information provided by (Responsible Party):
Mario H. Vargas, Instituto Nacional de Enfermedades Respiratorias
ClinicalTrials.gov Identifier:
NCT01417481
First received: August 15, 2011
Last updated: March 12, 2012
Last verified: March 2012
History of Changes
  Purpose

The aim of this study is to evaluate if glycine, orally administered in a daily dose of 0.5 g/kg during 8 weeks, can ameliorate the airway inflammation in children with cystic fibrosis, as compared with placebo. During all of the study children will receive their usual treatment for cystic fibrosis.


Condition Intervention Phase
Cystic Fibrosis
 Dietary Supplement: Glycine
Dietary Supplement: Placebo
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Instituto Nacional de Enfermedades Respiratorias:

Primary Outcome Measures:
  • Decrease of serum and sputum concentrations of inflammatory biomarkers in children with cystic fibrosis. [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    To determine whether a daily oral supplement of 0.5 g/kg glycine during 8 weeks significantly diminish the serum and sputum concentrations of inflammatory biomarkers in children with cystic fibrosis, including IL-1β, IL-6, IL-8, TNF-α, myeloperoxidase.


Secondary Outcome Measures:
  • Improvement of respiratory symptoms, sputum production, and spirometric variables [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    To determine whether a daily oral supplement of 0.5 g/kg glycine during 8 weeks improve respiratory symptoms, sputum production, and spirometric variables.


Estimated Enrollment: 30
Study Start Date: March 2012
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Glycine
Patients will receive a daily oral supplement of 0.5 g/kg glycine dissolved in water.
 Dietary Supplement: Glycine
Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
Other Name: aminoacetic acid
Placebo Comparator: Placebo
Patients will receive a daily supplement of 0.5 g/kg sugar glass dissolved in water.
 Dietary Supplement: Placebo
Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
Other Name: sugar glass

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   5 Years to 15 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children of either sex
  • Between 5 and 15 years of age
  • With CF diagnosed according to established criteria
  • Without changes in the CF treatment in the last 30 days
  • Without CF exacerbation in the last 30 days
  • Without acute respiratory infection (e.g., common cold) in the last 15 days
  • Informed consent letter signed by their parents or legal guardians

Exclusion Criteria:

  • Children with CF that had participated in a research protocol in the last 3 months
  • Presence of serious adverse effects attributable to glycine, in which case the result will be considered as therapeutic failure in the statistical analysis
  • Development of a CF exacerbation, in which case the available data so far collected will be included in the statistical analysis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01417481

Contacts
Contact: Rosangela Del Razo, MD (+55) 54871700 ext 5251 rosangelarr@yahoo.com

Locations
Mexico
Instituto Nacional de Enfermedades Respiratorias Recruiting
Mexico DF, Mexico, 14080
Principal Investigator: Mario H. Vargas, MD, MSc            
Sub-Investigator: Rosangela Del Razo, MD            
Sub-Investigator: Jaime Chávez-Alderete, PhD            
Hospital Infantil de México Recruiting
Mexico DF, Mexico, 06720
Contact: José L Lezana, MD     (+55) 52289917 ext 2093     lezana_doc@yahoo.com.mx    
Principal Investigator: José L Lezana, MD            
Unidad de Investigación Médica en Enfermedades Respiratorias, Hospital de Pediatría, CMN SXXI, IMSS Not yet recruiting
Mexico DF, Mexico, 06720
Sub-Investigator: Maria EY Furuya, PhD            
Sponsors and Collaborators
Instituto Nacional de Enfermedades Respiratorias
Hospital Infantil de Mexico Federico Gomez
Instituto Mexicano del Seguro Social
Investigators
Principal Investigator: Mario H Vargas, MD, MSc Instituto Nacional de Enfermedades Respiratorias
  More Information

Publications:

Responsible Party: Mario H. Vargas, Senior Researcher, Instituto Nacional de Enfermedades Respiratorias
ClinicalTrials.gov Identifier: NCT01417481     History of Changes
Other Study ID Numbers: Glycine in CF
Study First Received: August 15, 2011
Last Updated: March 12, 2012
Health Authority: Mexico: Ministry of Health

Keywords provided by Instituto Nacional de Enfermedades Respiratorias:
cystic fibrosis
glycine
airway inflammation

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Inflammation
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
 Infant, Newborn, Diseases
Pathologic Processes
Glycine
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 21, 2013